Td Asset Management Inc Prometheus Biosciences, Inc. Transaction History

Td Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$103.46 - $126.29 $1.26 Million - $1.54 Million	12,224 Added 29.56%	53,575 $5.75 Million
Q4 2022 Feb 06, 2023	BUY	$36.06 - $117.21 $892,521 - $2.9 Million	24,751 Added 149.1%	41,351 $4.55 Million
Q3 2022 Nov 07, 2022	BUY	$28.17 - $59.01 $467,622 - $979,566	16,600 New	16,600 $955,000
Q2 2021 Aug 11, 2021	SELL	$16.8 - $29.65 $579,012 - $1.02 Million	-34,465 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$16.51 - $25.29 $569,017 - $871,619	34,465 New	34,465 $629,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.